Intracellular galectins in cancer cells: Potential new targets for therapy (Review)

Vladoiu,Maria C.; Labrie,Marilyne; St-Pierre,Yves

doi:10.3892/ijo.2014.2267

Intracellular galectins in cancer cells: Potential new targets for therapy (Review)

Authors:
- Maria C. Vladoiu
- Marilyne Labrie
- Yves St-Pierre
View Affiliations

Affiliations: INRS-Institut Armand-Frappier, Laval, QC H7V 1B7, Canada
Published online on: January 21, 2014 https://doi.org/10.3892/ijo.2014.2267
Pages: 1001-1014

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulation of galectin expression is frequently observed in cancer tissues. Such an abnormal expression pattern often correlates with aggressiveness and relapse in many types of cancer. Because galectins have the ability to modulate functions that are important for cell survival, migration and metastasis, they also represent attractive targets for cancer therapy. This has been well-exploited for extracellular galectins, which bind glycoconjugates expressed on the surface of cancer cells. Although the existence of intracellular functions of galectins has been known for many years, an increasing number of studies indicate that these proteins can also alter tumor progression through their interaction with intracellular ligands. In fact, in some instances, the interactions of galectins with their intracellular ligands seem to occur independently of their carbohydrate recognition domain. Such findings call for a change in the basic assumptions, or paradigms, concerning the activity of galectins in cancer and may force us to revisit our strategies to develop galectin antagonists for the treatment of cancer.

View Figures

View References

1.	Levi G and Teichberg VI: Isolation and physicochemical characterization of electrolectin, a beta-D-galactoside binding lectin from the electric organ of Electrophorus electricus. J Biol Chem. 256:5735–5740. 1981.PubMed/NCBI
2.	Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, et al: Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev. Aug 1–2013.Epub ahead of print.
3.	Radosavljevic G, Volarevic V, Jovanovic I, et al: The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res. 52:100–110. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Van den Brule F, Califice S and Castronovo V: Expression of galectins in cancer: a critical review. Glycoconj J. 19:537–542. 2004.PubMed/NCBI
5.	Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Partridge EA, Le Roy C, Di Guglielmo GM, et al: Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 306:120–124. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Perillo NL, Uittenbogaart CH, Nguyen JT and Baum LG: Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med. 185:1851–1858. 1997. View Article : Google Scholar : PubMed/NCBI
8.	Chiariotti L, Salvatore P, Frunzio R and Bruni CB: Galectin genes: regulation of expression. Glycoconj J. 19:441–449. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Vyakarnam A, Lenneman AJ, Lakkides KM, Patterson RJ and Wang JL: A comparative nuclear localization study of galectin-1 with other splicing components. Exp Cell Res. 242:419–428. 1998. View Article : Google Scholar : PubMed/NCBI
10.	Ose R, Oharaa O and Nagase T: Galectin-1 and galectin-3 mediate protocadherin-24-dependent membrane localization of beta-catenin in colon cancer cell line HCT116. Curr Chem Genomics. 6:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Gabius HJ, Andre S, Gunsenhauser I, et al: Association of galectin-1- but not galectin-3-dependent parameters with proliferation activity in human neuroblastomas and small cell lung carcinomas. Anticancer Res. 22:405–410. 2002.PubMed/NCBI
12.	Biron VA, Iglesias MM, Troncoso MF, et al: Galectin-1: biphasic growth regulation of Leydig tumor cells. Glycobiology. 16:810–821. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Saussez S, Decaestecker C, Lorfevre F, et al: Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology. 52:483–493. 2008. View Article : Google Scholar
14.	Van den Brule FA, Buicu C, Baldet M, et al: Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun. 209:760–767. 1995.PubMed/NCBI
15.	Sanjuan X, Fernandez PL, Castells A, et al: Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology. 113:1906–1915. 1997. View Article : Google Scholar : PubMed/NCBI
16.	Dvorankova B, Lacina L, Smetana K Jr, et al: Human galectin-2: nuclear presence in vitro and its modulation by quiescence/stress factors. Histol Histopathol. 23:167–178. 2008.PubMed/NCBI
17.	Uhlen M, Oksvold P, Fagerberg L, et al: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Viaene AN, Petrof I and Sherman SM: Properties of the thalamic projection from the posterior medial nucleus to primary and secondary somatosensory cortices in the mouse. Proc Natl Acad Sci USA. 108:18156–18161. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Van den Brule FA, Buicu C, Berchuck A, et al: Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 27:1185–1191. 1996.PubMed/NCBI
20.	Mey A, Berthier-Vergnes O, Apoil PA, Dore JF and Revillard JP: Expression of the galactose binding protein Mac-2 by human melanoma cell-lines. Cancer Lett. 81:155–163. 1994. View Article : Google Scholar : PubMed/NCBI
21.	Matesa-Anic D, Moslavac S, Matesa N, Cupic H and Kusic Z: Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms. Acta Clin Croat. 51:237–241. 2012.PubMed/NCBI
22.	Lotz MM, Andrews CW Jr, Korzelius CA, et al: Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA. 90:3466–3470. 1993. View Article : Google Scholar : PubMed/NCBI
23.	Kawachi K, Matsushita Y, Yonezawa S, et al: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol. 31:428–433. 2000. View Article : Google Scholar : PubMed/NCBI
24.	Honjo Y, Inohara H, Akahani S, et al: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 6:4635–4640. 2000.PubMed/NCBI
25.	Kim DW, Kim KH, Yoo BC, et al: Identification of mitochondrial F(1)F(0)-ATP synthase interacting with galectin-3 in colon cancer cells. Cancer Sci. 99:1884–1891. 2008.PubMed/NCBI
26.	Lepur A, Carlsson MC, Novak R, Dumic J, Nilsson UJ and Leffler H: Galectin-3 endocytosis by carbohydrate independent and dependent pathways in different macrophage like cell types. Biochim Biophys Acta. 1820:804–818. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Huflejt ME, Jordan ET, Gitt MA, Barondes SH and Leffler H: Strikingly different localization of galectin-3 and galectin-4 in human colon adenocarcinoma T84 cells. Galectin-4 is localized at sites of cell adhesion. J Biol Chem. 272:14294–14303. 1997. View Article : Google Scholar : PubMed/NCBI
28.	Huflejt ME and Leffler H: Galectin-4 in normal tissues and cancer. Glycoconj J. 20:247–255. 2004. View Article : Google Scholar
29.	Belo AI, van der Sar AM, Tefsen B and van Die I: Galectin-4 reduces migration and metastasis formation of pancreatic cancer cells. PLoS One. 8:e659572013. View Article : Google Scholar : PubMed/NCBI
30.	Kuwabara I, Kuwabara Y, Yang RY, et al: Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem. 277:3487–3497. 2002. View Article : Google Scholar : PubMed/NCBI
31.	Kim HJ, Jeon HK, Lee JK, et al: Clinical significance of galectin-7 in epithelial ovarian cancer. Anticancer Res. 33:1555–1561. 2013.PubMed/NCBI
32.	De Vasconcelos Carvalho M, Pereira Jdos S, Alves PM, Silveira EJ, de Souza LB and Queiroz LM: Alterations in the immunoexpression of galectins-1, -3 and -7 between different grades of oral epithelial dysplasia. J Oral Pathol Med. 42:174–179. 2013.PubMed/NCBI
33.	Villeneuve C, Baricault L, Canelle L, et al: Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol Biol Cell. 22:999–1013. 2011. View Article : Google Scholar : PubMed/NCBI
34.	Delgado VM, Nugnes LG, Colombo LL, et al: Modulation of endothelial cell migration and angiogenesis: a novel function for the ‘tandem-repeat’ lectin galectin-8. FASEB J. 25:242–254. 2011.
35.	Kageshita T, Kashio Y, Yamauchi A, et al: Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
36.	Irie A, Yamauchi A, Kontani K, et al: Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
37.	Rousseau C, Muriel MP, Musset M, Botti J and Seve AP: Glycosylated nuclear lectin CBP70 also associated with endoplasmic reticulum and the Golgi apparatus: does the ‘classic pathway’ of glycosylation also apply to nuclear glycoproteins? J Cell Biochem. 78:638–649. 2000.PubMed/NCBI
38.	Hotta K, Funahashi T, Matsukawa Y, et al: Galectin-12, an adipose-expressed galectin-like molecule possessing apoptosis-inducing activity. J Biol Chem. 276:34089–34097. 2001. View Article : Google Scholar : PubMed/NCBI
39.	Wang JL, Gray RM, Haudek KC and Patterson RJ: Nucleocytoplasmic lectins. Biochim Biophys Acta. 1673:75–93. 2004. View Article : Google Scholar : PubMed/NCBI
40.	Carlsson S, Carlsson MC and Leffler H: Intracellular sorting of galectin-8 based on carbohydrate fine specificity. Glycobiology. 17:906–912. 2007. View Article : Google Scholar : PubMed/NCBI
41.	Yang RY, Yu L, Graham JL, et al: Ablation of a galectin preferentially expressed in adipocytes increases lipolysis, reduces adiposity, and improves insulin sensitivity in mice. Proc Natl Acad Sci USA. 108:18696–18701. 2011. View Article : Google Scholar : PubMed/NCBI
42.	Baum LG: Burn control, an adipocyte-specific function for galectin-12. Proc Natl Acad Sci USA. 108:18575–18576. 2011. View Article : Google Scholar : PubMed/NCBI
43.	Kubach J, Lutter P, Bopp T, et al: Human CD4⁺CD25⁺ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood. 110:1550–1558. 2007.PubMed/NCBI
44.	Than NG, Pick E, Bellyei S, et al: Functional analyses of placental protein 13/galectin-13. Eur J Biochem. 271:1065–1078. 2004. View Article : Google Scholar : PubMed/NCBI
45.	Nakai K and Horton P: PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci. 24:34–36. 1999. View Article : Google Scholar : PubMed/NCBI
46.	Nakai K and Kanehisa M: A knowledge base for predicting protein localization sites in eukaryotic cells. Genomics. 14:897–911. 1992. View Article : Google Scholar : PubMed/NCBI
47.	Califice S, Castronovo V, Bracke M and van den Brule F: Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene. 23:7527–7536. 2004. View Article : Google Scholar : PubMed/NCBI
48.	St-Pierre Y, Campion CG and Grosset AA: A distinctive role for galectin-7 in cancer? Front Biosci (Landmark Ed). 17:438–450. 2012. View Article : Google Scholar
49.	Chiariotti L, Berlingieri MT, De Rosa P, et al: Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene. 7:2507–2511. 1992.
50.	Xu XC, el-Naggar AK and Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 147:815–822. 1995.PubMed/NCBI
51.	Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y and Kirino T: Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res. 59:722–730. 2000. View Article : Google Scholar : PubMed/NCBI
52.	Paz A, Haklai R, Elad-Sfadia G, Ballan E and Kloog Y: Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene. 20:7486–7493. 2001. View Article : Google Scholar : PubMed/NCBI
53.	Elad-Sfadia G, Haklai R, Balan E and Kloog Y: Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem. 279:34922–34930. 2004. View Article : Google Scholar : PubMed/NCBI
54.	Shalom-Feuerstein R, Levy R, Makovski V, Raz A and Kloog Y: Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim Biophys Acta. 1783:985–993. 2008. View Article : Google Scholar : PubMed/NCBI
55.	Hebert E and Monsigny M: Galectin-3 mRNA level depends on transformation phenotype in ras-transformed NIH 3T3 cells. Biol Cell. 81:73–76. 1994. View Article : Google Scholar : PubMed/NCBI
56.	Hebert E, Roche AC, Nachtigal M and Monsigny M: Transformation but not ras-transfection increases the expression of galectin-3 in human HOS cells. C R Acad Sci III. 319:871–877. 1996.PubMed/NCBI
57.	Park JW, Voss PG, Grabski S, Wang JL and Patterson RJ: Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res. 29:3595–3602. 2001. View Article : Google Scholar : PubMed/NCBI
58.	Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D and Lotan R: Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Int J Oncol. 14:225–232. 1999.PubMed/NCBI
59.	Horiguchi N, Arimoto K, Mizutani A, Endo-Ichikawa Y, Nakada H and Taketani S: Galectin-1 induces cell adhesion to the extracellular matrix and apoptosis of non-adherent human colon cancer Colo201 cells. J Biochem. 134:869–874. 2003. View Article : Google Scholar : PubMed/NCBI
60.	Fouillit M, Joubert-Caron R, Poirier F, et al: Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B cells. Glycobiology. 10:413–419. 2000. View Article : Google Scholar : PubMed/NCBI
61.	Poirier F, Bourin P, Bladier D, Joubert-Caron R and Caron M: Effect of 5-azacytidine and galectin-1 on growth and differentiation of the human b lymphoma cell line bl36. Cancer Cell Int. 1:22001. View Article : Google Scholar : PubMed/NCBI
62.	Huang EY, Chen YF, Chen YM, et al: A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Dis. 3:e2512012. View Article : Google Scholar : PubMed/NCBI
63.	Chung LY, Tang SJ, Sun GH, et al: Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res. 18:4037–4047. 2012. View Article : Google Scholar : PubMed/NCBI
64.	Kim HJ, Jeon HK, Cho YJ, et al: High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
65.	Mazurek N, Byrd JC, Sun Y, et al: Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 19:523–533. 2012. View Article : Google Scholar : PubMed/NCBI
66.	Shi Y, He B, Kuchenbecker KM, et al: Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer. 121:1175–1181. 2007. View Article : Google Scholar : PubMed/NCBI
67.	Matarrese P, Fusco O, Tinari N, et al: Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer. 85:545–554. 2000. View Article : Google Scholar : PubMed/NCBI
68.	Moon BK, Lee YJ, Battle P, Jessup JM, Raz A and Kim HR: Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol. 159:1055–1060. 2001. View Article : Google Scholar
69.	Fukumori T, Oka N, Takenaka Y, et al: Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 66:3114–3119. 2006. View Article : Google Scholar : PubMed/NCBI
70.	Lavra L, Ulivieri A, Rinaldo C, et al: Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol. 218:66–75. 2009. View Article : Google Scholar : PubMed/NCBI
71.	Lin CI, Whang EE, Abramson MA, et al: Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun. 379:626–631. 2009. View Article : Google Scholar : PubMed/NCBI
72.	Lin CI, Whang EE, Donner DB, et al: Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res. 7:1655–1662. 2009. View Article : Google Scholar : PubMed/NCBI
73.	Hoyer KK, Pang M, Gui D, et al: An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol. 164:893–902. 2004. View Article : Google Scholar : PubMed/NCBI
74.	Cheng YL, Huang WC, Chen CL, et al: Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun. 412:334–340. 2011. View Article : Google Scholar : PubMed/NCBI
75.	Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al: Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 108:17468–17473. 2011. View Article : Google Scholar : PubMed/NCBI
76.	Oka N, Nakahara S, Takenaka Y, et al: Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 65:7546–7553. 2005.
77.	Kobayashi T, Shimura T, Yajima T, et al: Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer. 129:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI
78.	Cheong TC, Shin JY and Chun KH: Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci. 101:94–102. 2010. View Article : Google Scholar : PubMed/NCBI
79.	Veschi V, Petroni M, Cardinali B, et al: Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One. 7:e491392012. View Article : Google Scholar : PubMed/NCBI
80.	Xu Y, Gu X, Gong M, Guo G, Han K and An R: Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. Cancer Biol Ther. 14:897–906. 2013. View Article : Google Scholar : PubMed/NCBI
81.	Suzuki O and Abe M: Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma. Oncol Rep. 19:743–748. 2008.PubMed/NCBI
82.	Demers M, Rose AA, Grosset AA, et al: Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol. 176:3023–3031. 2010. View Article : Google Scholar : PubMed/NCBI
83.	Ueda S, Kuwabara I and Liu FT: Suppression of tumor growth by galectin-7 gene transfer. Cancer Res. 64:5672–5676. 2004. View Article : Google Scholar : PubMed/NCBI
84.	Biron-Pain K, Grosset AA, Poirier F, Gaboury L and St-Pierre Y: Expression and functions of galectin-7 in human and murine melanomas. PLoS One. 8:e633072013. View Article : Google Scholar : PubMed/NCBI
85.	Matsui Y, Ueda S, Watanabe J, Kuwabara I, Ogawa O and Nishiyama H: Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res. 67:1212–1220. 2007. View Article : Google Scholar : PubMed/NCBI
86.	Tsai CJ, Sulman EP, Eifel PJ, et al: Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol. Apr 30–2013.Epub ahead of print.
87.	Zhu H, Wu TC, Chen WQ, et al: Roles of galectin-7 and S100A9 in cervical squamous carcinoma: Clinicopathological and in vitro evidence. Int J Cancer. 132:1051–1059. 2013. View Article : Google Scholar : PubMed/NCBI
88.	Wiersma VR, de Bruyn M, van Ginkel RJ, et al: The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J Invest Dermatol. 132:2302–2305. 2012. View Article : Google Scholar : PubMed/NCBI
89.	Yang RY, Hsu DK and Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA. 93:6737–6742. 1996. View Article : Google Scholar : PubMed/NCBI
90.	Akahani S, Nangia-Makker P, Inohara H, Kim HR and Raz A: Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 57:5272–5276. 1997.PubMed/NCBI
91.	Dumic J, Dabelic S and Flogel M: Galectin-3: an open-ended story. Biochim Biophys Acta. 1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
92.	Fukumori T, Takenaka Y, Oka N, et al: Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res. 64:3376–3379. 2004. View Article : Google Scholar : PubMed/NCBI
93.	Kopitz J, von Reitzenstein C, Andre S, et al: Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem. 276:35917–35923. 2001. View Article : Google Scholar : PubMed/NCBI
94.	Jiang HB, Xu M and Wang XP: Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3. World J Gastroenterol. 14:2023–2028. 2008. View Article : Google Scholar : PubMed/NCBI
95.	Song S, Ji B, Ramachandran V, et al: Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One. 7:e426992012. View Article : Google Scholar : PubMed/NCBI
96.	Wang LP, Chen SW, Zhuang SM, Li H and Song M: Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/beta-catenin-dependent pathway. Pathol Oncol Res. 19:461–474. 2013. View Article : Google Scholar : PubMed/NCBI
97.	Zhang D, Chen ZG, Liu SH, et al: Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating beta-catenin. Acta Pharmacol Sin. 34:176–184. 2013. View Article : Google Scholar : PubMed/NCBI
98.	Kim HR, Lin HM, Biliran H and Raz A: Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 59:4148–4154. 1999.PubMed/NCBI
99.	Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of beta-catenin. Cancer Res. 64:6363–6367. 2004. View Article : Google Scholar : PubMed/NCBI
100.	Kim SW, Park KC, Jeon SM, et al: Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. Cell Oncol (Dordr). 36:169–178. 2013. View Article : Google Scholar : PubMed/NCBI
101.	Satelli A, Rao PS, Thirumala S and Rao US: Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer. 129:799–809. 2011. View Article : Google Scholar : PubMed/NCBI
102.	Guo J, Cagatay T, Zhou G, et al: Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling. PLoS One. 4:e79822009. View Article : Google Scholar : PubMed/NCBI
103.	Kim SJ, Hwang JA, Ro JY, Lee YS and Chun KH: Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget. 4:1461–1471. 2013.PubMed/NCBI
104.	Kopitz J, Andre S, von Reitzenstein C, et al: Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene. 22:6277–6288. 2003. View Article : Google Scholar : PubMed/NCBI
105.	Kobayashi T, Kuroda J, Ashihara E, et al: Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
106.	Nagy N, Bronckart Y, Camby I, et al: Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut. 50:392–401. 2002. View Article : Google Scholar : PubMed/NCBI
107.	Yang RY, Hsu DK, Yu L, Ni J and Liu FT: Cell cycle regulation by galectin-12, a new member of the galectin superfamily. J Biol Chem. 276:20252–20260. 2001. View Article : Google Scholar : PubMed/NCBI
108.	Clausse N, van den Brule F, Waltregny D, Garnier F and Castronovo V: Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis. 3:317–325. 1999. View Article : Google Scholar : PubMed/NCBI
109.	Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS and Kuo PL: Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis. 34:1370–1381. 2013. View Article : Google Scholar : PubMed/NCBI
110.	Hittelet A, Legendre H, Nagy N, et al: Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer. 103:370–379. 2003. View Article : Google Scholar : PubMed/NCBI
111.	Spano D, Russo R, Di Maso V, et al: Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med. 16:102–115. 2010. View Article : Google Scholar : PubMed/NCBI
112.	Jung TY, Jung S, Ryu HH, et al: Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg. 109:273–284. 2008. View Article : Google Scholar : PubMed/NCBI
113.	Rorive S, Belot N, Decaestecker C, et al: Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia. 33:241–255. 2001. View Article : Google Scholar : PubMed/NCBI
114.	Xue X, Lu Z, Tang D, et al: Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an in vitro study on the microenvironment of pancreatic ductal adenocarcinoma. Pancreas. 40:832–839. 2011. View Article : Google Scholar
115.	Kim HJ, Do IG, Jeon HK, et al: Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum Pathol. 44:62–68. 2013. View Article : Google Scholar : PubMed/NCBI
116.	Barrow H, Guo X, Wandall HH, et al: Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 17:7035–7046. 2011. View Article : Google Scholar : PubMed/NCBI
117.	O’Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I and Clynes M: Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res. 22:3117–3125. 2002.PubMed/NCBI
118.	Kim SJ, Choi IJ, Cheong TC, et al: Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology. 138:1035–1045.e2. 2010. View Article : Google Scholar : PubMed/NCBI
119.	Kim SJ, Shin JY, Lee KD, et al: Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One. 6:e251032011. View Article : Google Scholar : PubMed/NCBI
120.	Wang Y, Nangia-Makker P, Tait L, et al: Regulation of prostate cancer progression by galectin-3. Am J Pathol. 174:1515–1523. 2009. View Article : Google Scholar : PubMed/NCBI
121.	Debray C, Vereecken P, Belot N, et al: Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun. 325:1393–1398. 2004. View Article : Google Scholar : PubMed/NCBI
122.	Braeuer RR, Zigler M, Kamiya T, et al: Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 72:5757–5766. 2012. View Article : Google Scholar : PubMed/NCBI
123.	Radosavljevic G, Jovanovic I, Majstorovic I, et al: Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis. 28:451–462. 2011. View Article : Google Scholar : PubMed/NCBI
124.	Inufusa H, Nakamura M, Adachi T, et al: Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol. 19:913–919. 2001.PubMed/NCBI
125.	Bresalier RS, Mazurek N, Sternberg LR, et al: Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology. 115:287–296. 1998. View Article : Google Scholar : PubMed/NCBI
126.	Ellerhorst JA, Stephens LC, Nguyen T and Xu XC: Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate. 50:64–70. 2002. View Article : Google Scholar : PubMed/NCBI
127.	Demers M, Biron-Pain K, Hebert J, Lamarre A, Magnaldo T and St-Pierre Y: Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model. Cancer Res. 67:2824–2829. 2007. View Article : Google Scholar
128.	Demers M, Magnaldo T and St-Pierre Y: A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res. 65:5205–5210. 2005. View Article : Google Scholar : PubMed/NCBI
129.	Moisan S, Demers M, Mercier J, Magnaldo T, Potworowski EF and St-Pierre Y: Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia. 17:751–759. 2003. View Article : Google Scholar : PubMed/NCBI
130.	Park JE, Chang WY and Cho M: Induction of matrix metal-loproteinase-9 by galectin-7 through p38 MAPK signaling in HeLa human cervical epithelial adenocarcinoma cells. Oncol Rep. 22:1373–1379. 2009.PubMed/NCBI
131.	Camby I, Belot N, Rorive S, et al: Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol. 11:12–26. 2001. View Article : Google Scholar
132.	Kasamatsu A, Uzawa K, Nakashima D, et al: Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med. 16:269–273. 2005.PubMed/NCBI
133.	Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H and Hirashima M: Galectin-9, a novel prognostic factor with anti-metastatic potential in breast cancer. Breast J. 12:S196–S200. 2006. View Article : Google Scholar : PubMed/NCBI
134.	Zhang F, Zheng M, Qu Y, et al: Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells. Mol Biol Rep. 36:823–830. 2009. View Article : Google Scholar : PubMed/NCBI
135.	Zhang F, Zheng MH, Qu Y, et al: Galectin-9 isoforms influence the adhesion between colon carcinoma LoVo cells and human umbilical vein endothelial cells in vitro by regulating the expression of E-selectin in LoVo cells. Zhonghua Zhong Liu Za Zhi. 31:95–98. 2009.In Chinese.
136.	Nobumoto A, Nagahara K, Oomizu S, et al: Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 18:735–744. 2008. View Article : Google Scholar : PubMed/NCBI
137.	Le Mercier M, Mathieu V, Haibe-Kains B, et al: Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol. 67:456–469. 2008.PubMed/NCBI
138.	Ito K, Scott SA, Cutler S, et al: Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis. 14:293–307. 2011. View Article : Google Scholar
139.	Mourad-Zeidan AA, Melnikova VO, Wang H, Raz A and Bar-Eli M: Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol. 173:1839–1852. 2008. View Article : Google Scholar : PubMed/NCBI
140.	Daroqui CM, Ilarregui JM, Rubinstein N, et al: Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol Immunother. 56:491–499. 2007. View Article : Google Scholar : PubMed/NCBI
141.	He J and Baum LG: Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest. 86:578–590. 2006.PubMed/NCBI
142.	Tang D, Yuan Z, Xue X, et al: High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer. 130:2337–2348. 2012. View Article : Google Scholar : PubMed/NCBI
143.	Peng W, Wang HY, Miyahara Y, Peng G and Wang RF: Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 68:7228–7236. 2008. View Article : Google Scholar : PubMed/NCBI
144.	Troncoso MF, Elola MT, Croci DO and Rabinovich GA: Integrating structure and function of ‘tandem-repeat’ galectins. Front Biosci (Schol Ed). 4:864–887. 2012.
145.	Scott K and Weinberg C: Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J. 19:467–477. 2004. View Article : Google Scholar : PubMed/NCBI
146.	Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JL and Arnoys EJ: Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta. 1800:181–189. 2010. View Article : Google Scholar : PubMed/NCBI
147.	Shimura T, Takenaka Y, Fukumori T, et al: Implication of galectin-3 in Wnt signaling. Cancer Res. 65:3535–3537. 2005. View Article : Google Scholar : PubMed/NCBI
148.	Ackerman SJ, Liu L, Kwatia MA, et al: Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem. 277:14859–14868. 2002. View Article : Google Scholar : PubMed/NCBI
149.	Swaminathan GJ, Leonidas DD, Savage MP, Ackerman SJ and Acharya KR: Selective recognition of mannose by the human eosinophil Charcot-Leyden crystal protein (galectin-10): a crystallographic study at 1.8 A resolution. Biochemistry. 38:13837–13843. 1999. View Article : Google Scholar
150.	Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS and Rao US: Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep. 19:587–594. 2008.PubMed/NCBI
151.	Mbeunkui F, Metge BJ, Shevde LA and Pannell LK: Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res. 6:2993–3002. 2007. View Article : Google Scholar : PubMed/NCBI
152.	Khaldoyanidi SK, Glinsky VV, Sikora L, et al: MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem. 278:4127–4134. 2003. View Article : Google Scholar : PubMed/NCBI
153.	Inohara H and Raz A: Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J. 11:527–532. 1994. View Article : Google Scholar : PubMed/NCBI
154.	Pienta KJ, Naik H, Akhtar A, et al: Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 87:348–353. 1995. View Article : Google Scholar : PubMed/NCBI
155.	Nangia-Makker P, Hogan V, Honjo Y, et al: Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 94:1854–1862. 2002. View Article : Google Scholar : PubMed/NCBI
156.	Dings RP, Miller MC, Nesmelova I, et al: Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem. 55:5121–5129. 2012. View Article : Google Scholar : PubMed/NCBI
157.	Chiariotti L, Berlingieri MT, Battaglia C, et al: Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer. 64:171–175. 1995. View Article : Google Scholar : PubMed/NCBI
158.	Ellerhorst J, Nguyen T, Cooper DN, Lotan D and Lotan R: Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol. 14:217–224. 1999.PubMed/NCBI
159.	Laderach DJ, Gentilini LD, Giribaldi L, et al: A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 73:86–96. 2013. View Article : Google Scholar : PubMed/NCBI
160.	Jung EJ, Moon HG, Cho BI, et al: Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer. 120:2331–2338. 2007. View Article : Google Scholar : PubMed/NCBI
161.	Dalotto-Moreno T, Croci DO, Cerliani JP, et al: Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 73:1107–1117. 2013. View Article : Google Scholar
162.	Zhao XY, Chen TT, Xia L, et al: Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis. 31:1367–1375. 2010. View Article : Google Scholar : PubMed/NCBI
163.	Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ and Kiss R: Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun. 335:27–35. 2005. View Article : Google Scholar : PubMed/NCBI
164.	Strik HM, Schmidt K, Lingor P, et al: Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep. 18:483–488. 2007.PubMed/NCBI
165.	Le Mercier M, Lefranc F, Mijatovic T, et al: Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol. 229:172–183. 2008.PubMed/NCBI
166.	Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S and Liu FT: Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer. 91:167–172. 2001. View Article : Google Scholar : PubMed/NCBI
167.	Wu KL, Huang EY, Jhu EW, et al: Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol. 48:350–359. 2013. View Article : Google Scholar : PubMed/NCBI
168.	Honjo Y, Nangia-Makker P, Inohara H and Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 7:661–668. 2001.PubMed/NCBI
169.	Shekhar MP, Nangia-Makker P, Tait L, Miller F and Raz A: Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 165:1931–1941. 2004. View Article : Google Scholar
170.	Baptiste TA, James A, Saria M and Ochieng J: Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extra-cellular functions of the lectin. Exp Cell Res. 313:652–664. 2007. View Article : Google Scholar
171.	Van den Brule FA, Waltregny D, Liu FT and Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer. 89:361–367. 2000.PubMed/NCBI
172.	Yoshii T, Inohara H, Takenaka Y, et al: Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol. 18:787–792. 2001.PubMed/NCBI
173.	Takenaka Y, Inohara H, Yoshii T, et al: Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 195:111–119. 2003. View Article : Google Scholar : PubMed/NCBI
174.	Shankar J, Wiseman SM, Meng F, et al: Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer. J Pathol. 228:56–66. 2012.PubMed/NCBI
175.	Li W, Jian-jun W, Xue-Feng Z and Feng Z: CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of CD8(+) T cells by highly expressed galectin-3. Clin Invest Med. 33:E44–E53. 2010.
176.	Clark MC, Pang M, Hsu DK, et al: Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood. 120:4635–4644. 2012. View Article : Google Scholar : PubMed/NCBI
177.	Srinivasan N, Bane SM, Ahire SD, Ingle AD and Kalraiya RD: Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J. 26:445–456. 2009. View Article : Google Scholar : PubMed/NCBI
178.	Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY and Chun KH: Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med. 44:387–393. 2012. View Article : Google Scholar : PubMed/NCBI
179.	Oishi T, Itamochi H, Kigawa J, et al: Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer. 17:1040–1046. 2007. View Article : Google Scholar : PubMed/NCBI
180.	Kim MK, Sung CO, Do IG, et al: Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol. 16:352–358. 2011. View Article : Google Scholar : PubMed/NCBI
181.	Merlin J, Stechly L, de Beauce S, et al: Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene. 30:2514–2525. 2011. View Article : Google Scholar : PubMed/NCBI
182.	Kobayashi T, Shimura T, Yajima T, et al: Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clin Exp Metastasis. 28:367–376. 2011. View Article : Google Scholar : PubMed/NCBI
183.	Ideo H, Seko A and Yamashita K: Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface of human colon adenocarcinoma cells. J Biol Chem. 280:4730–4737. 2005. View Article : Google Scholar : PubMed/NCBI
184.	Kuroda J, Yamamoto M, Nagoshi H, et al: Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res. 8:994–1001. 2010. View Article : Google Scholar
185.	Gonzalez MM, Yoshizaki L, Wolfenstein-Todel C and Fink NE: Isolation of galectin-1 from human platelets: its interaction with actin. Protein J. 31:8–14. 2012. View Article : Google Scholar : PubMed/NCBI
186.	Pace KE, Lee C, Stewart PL and Baum LG: Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol. 163:3801–3811. 1999.PubMed/NCBI
187.	Liu L, Sakai T, Sano N and Fukui K: Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J. 380:31–41. 2004. View Article : Google Scholar : PubMed/NCBI
188.	Seve AP, Felin M, Doyennette-Moyne MA, Sahraoui T, Aubery M and Hubert J: Evidence for a lactose-mediated association between two nuclear carbohydrate-binding proteins. Glycobiology. 3:23–30. 1993. View Article : Google Scholar : PubMed/NCBI
189.	Paron I, Scaloni A, Pines A, et al: Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun. 302:545–553. 2003. View Article : Google Scholar : PubMed/NCBI
190.	Vito P, Pellegrini L, Guiet C and D’Adamio L: Cloning of AIP1, a novel protein that associates with the apoptosis-linked gene ALG-2 in a Ca²⁺-dependent reaction. J Biol Chem. 274:1533–1540. 1999. View Article : Google Scholar : PubMed/NCBI
191.	Missotten M, Nichols A, Rieger K and Sadoul R: Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ. 6:124–129. 1999. View Article : Google Scholar : PubMed/NCBI
192.	Liu FT, Patterson RJ and Wang JL: Intracellular functions of galectins. Biochim Biophys Acta. 1572:263–273. 2002. View Article : Google Scholar : PubMed/NCBI
193.	Menon RP, Strom M and Hughes RC: Interaction of a novel cysteine and histidine-rich cytoplasmic protein with galectin-3 in a carbohydrate-independent manner. FEBS Lett. 470:227–231. 2000. View Article : Google Scholar : PubMed/NCBI
194.	Bawumia S, Barboni EA, Menon RP and Hughes RC: Specificity of interactions of galectin-3 with Chrp, a cysteineand histidine-rich cytoplasmic protein. Biochimie. 85:189–194. 2003. View Article : Google Scholar : PubMed/NCBI
195.	Inagaki Y, Higashi K, Kushida M, et al: Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology. 134:1180–1190. 2008. View Article : Google Scholar : PubMed/NCBI